fda approved glp-1 drugs for weight loss Market Overview: Agonists and the Obesity Market | Blog GLP-1 Genetics: How Genes Affect

Among these, autosomal dominant forms include mutations in SNCA (PARK1), UCHL1 , LRRK2 (PARK8), CHCHD2 , GBA , and VPS35 (PARK17), whereas autosomal recessive forms involve PARK2 (parkin), PINK1 (PARK6), DJ-1 (PARK7), and ATP13A2 (PARK9) (260)

These drugs are more suitable for long-term use as studies have shown that about two-thirds of people regain the lost weight once the drug is stopped

[7] This is why the two are frequently studied as complementary rather than competing mechanisms: the entire rationale for the CagriSema combination is that pairing an amylin analog (cagrilintide) with a GLP-1 analog (semaglutide) engages two different hormone systems together

Critically, comparable weight loss was not observed in RAMP1/RAMP3 knockout mice, confirming that the effect depends on AMYR and AMYR signaling rather than CTR activation alone

This technocratic framing depoliticizes projects, obscuring social inequalities, and limiting the inclusion of marginalized groups in decision-making